The RTS,S vaccine-a chance to regain the upper hand against malaria?

Photini Sinnis; David A Fidock

doi:10.1016/j.cell.2022.01.028

The RTS,S vaccine-a chance to regain the upper hand against malaria?

Cell. 2022 Mar 3;185(5):750-754. doi: 10.1016/j.cell.2022.01.028.

Authors

Photini Sinnis¹, David A Fidock²

Affiliations

¹ Johns Hopkins Malaria Research Institute and Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA. Electronic address: psinnis1@jhu.edu.
² Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, NY 10032, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA. Electronic address: df2260@cumc.columbia.edu.

Abstract

Malaria is estimated by the World Health Organization (WHO) to have killed 627,000 individuals worldwide in 2020, with nearly 80% of deaths in African children younger than five. The recent WHO approval of the RTS,S/AS01 vaccine, which targets Plasmodium falciparum pre-erythrocytic stages, provides hope that its use combined with other interventions can help reverse the current malaria resurgence.

MeSH terms

Child
Humans
Infant
Malaria Vaccines*
Malaria* / prevention & control
Malaria, Falciparum* / prevention & control
Plasmodium falciparum

Substances

Malaria Vaccines

Grants and funding

R01 AI132359/AI/NIAID NIH HHS/United States